Since the start of the pandemic, thrombotic events have been a well-known and severe
complication associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection. Nevertheless, the initiation of vaccination programs brought another rare
yet highly fatal thrombotic event, vaccine-induced immune thrombotic thrombocytopaenia,
which has caused extensive debate regarding the safety of vaccines. This review defines
the thromboembolic events following infection and vaccination, identifies their risk
factors, describes their pathophysiology, and discusses their management, treatment,
and prevention.
